Description
Cartalax 20mg – AED Tripeptide and Cartilage Cell Research Australia
Cartalax 20mg is a synthetic tripeptide research material listed by Peps Aussie Australia for scientific investigation, laboratory analysis and controlled experimental research.
Cartalax is commonly identified as Ala–Glu–Asp (AED), a short peptide consisting of three amino acid residues:
- Alanine (Ala)
- Glutamic acid (Glu)
- Aspartic acid (Asp)
The peptide is associated with a broader category of experimental compounds commonly described as peptide bioregulators.
These short peptides have been investigated in selected experimental models involving cellular signalling, gene expression and tissue-associated biological processes.
Cartalax has attracted scientific interest because published cell-based investigations have considered cartilage-related cells, molecular regulation and broader tissue biology.
Cartilage is a specialised connective tissue containing cells known as chondrocytes, which participate in maintaining the extracellular matrix.
Experimental research involving cartilage-related cells provides a context for investigating cellular regulation and tissue-associated molecular pathways.
However, cellular findings do not establish that Cartalax repairs cartilage, regenerates joints, treats osteoarthritis or improves mobility in humans.
The available evidence for Cartalax is limited, and claims about clinical cartilage regeneration or joint restoration exceed what can be established from published laboratory findings.
Peps Aussie lists Cartalax in a nominal 20mg size for laboratory research and analytical applications.
Important: Cartalax is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, joint treatment, tissue regeneration, therapeutic use or clinical applications.
What Is Cartalax?
Cartalax is a commercial and research designation commonly associated with the synthetic tripeptide Ala–Glu–Asp, abbreviated AED.
A tripeptide is a molecule consisting of three amino acid residues connected by peptide bonds.
Cartalax is commonly discussed in relation to experimental peptide-bioregulator research.
Cartalax Amino Acid Sequence
The commonly reported Cartalax sequence is:
Ala–Glu–Asp (AED)
The three amino acid residues are:
- Alanine (Ala/A): A small, nonpolar amino acid.
- Glutamic acid (Glu/E): An acidic amino acid.
- Aspartic acid (Asp/D): An acidic amino acid.
The exact amino acid sequence, stereochemistry, terminal modifications and salt form of the supplied material must be verified against the applicable lot documentation.
Understanding Peptide Bioregulators
Peptide bioregulators are a category of short peptides investigated for potential interactions with cellular regulatory processes.
Research involving these compounds has examined areas such as:
- Cellular signalling.
- Gene expression.
- Tissue-associated biology.
- Cell differentiation.
- Extracellular matrix regulation.
- Experimental ageing models.
- Molecular interactions.
- Analytical peptide chemistry.
However, peptide bioregulator is a research and commercial classification rather than proof of a specific therapeutic mechanism.
The biological activity of a particular peptide must be established through appropriate experimental evidence.
Cartalax Peptide Research and Scientific Applications
Published research associated with Cartalax and related short peptide bioregulators includes investigations involving cartilage-related cells, cellular regulation and gene expression.
The following sections describe scientific research topics rather than proven therapeutic effects of the Peps Aussie material.
1. Cartilage Cell Biology Research
One of the principal research areas associated with Cartalax involves cartilage-related cellular models.
Cartilage contains specialised cells called chondrocytes.
These cells participate in the maintenance and regulation of cartilage extracellular matrix components.
Relevant research topics include:
- Chondrocyte biology.
- Cartilage-associated cell models.
- Cellular signalling.
- Experimental tissue biology.
- Cell-associated molecular responses.
- Cartilage matrix regulation.
- Comparative cellular assays.
These investigations contribute to understanding cartilage-related cellular processes.
However, observations in cultured cells do not establish that Cartalax restores cartilage in living organisms.
2. Gene Expression Research
Gene expression research examines how cells regulate the production of RNA and proteins.
Short peptide bioregulators have been investigated in selected experimental systems for possible associations with gene expression patterns.
Relevant research topics include:
- Gene transcription.
- Cellular regulatory pathways.
- RNA-associated measurements.
- Protein expression.
- Experimental gene expression assays.
- Molecular response profiling.
- Comparative cellular models.
These investigations contribute to understanding cellular regulation.
However, a change in gene expression does not independently establish a beneficial biological outcome.
The significance of any observed changes depends on the experimental model, methodology and supporting functional evidence.
3. Extracellular Matrix Research
The extracellular matrix is a structural network surrounding cells in tissues.
Cartilage extracellular matrix contains components such as collagen and proteoglycans.
Research involving cartilage-related cells may investigate the regulation of these structural components.
Relevant research topics include:
- Extracellular matrix biology.
- Collagen-associated pathways.
- Proteoglycan regulation.
- Cartilage structural proteins.
- Cellular matrix interactions.
- Experimental tissue models.
- Molecular regulation of connective tissue.
These investigations contribute to understanding cartilage and connective tissue biology.
However, research into extracellular matrix pathways does not establish that Cartalax stimulates cartilage regeneration or repairs damaged joints.
4. Cellular Differentiation Research
Cellular differentiation refers to processes through which cells develop specialised characteristics.
Experimental cartilage biology includes investigations into chondrocyte differentiation and related molecular pathways.
Relevant research topics include:
- Cellular differentiation.
- Chondrocyte-associated markers.
- Gene expression patterns.
- Tissue-specific cellular characteristics.
- Experimental cell culture models.
- Molecular regulatory mechanisms.
- Comparative cellular responses.
These investigations contribute to understanding how cartilage-associated cells develop and maintain their specialised functions.
However, any Cartalax-specific effects require direct experimental evidence and should not be inferred from general cartilage biology.
5. Tissue Biology and Connective Tissue Research
Cartilage is one of several connective tissues that provide structural support within the body.
Research involving cartilage-associated peptides may also intersect with broader connective tissue biology.
Relevant research topics include:
- Connective tissue cell biology.
- Tissue-associated signalling.
- Cellular matrix interactions.
- Experimental tissue models.
- Structural protein regulation.
- Molecular tissue responses.
- Comparative peptide research.
These investigations contribute to understanding tissue biology.
However, findings involving one tissue model should not automatically be applied to another.
6. Cellular Ageing and Tissue-Associated Research
Ageing-related biological research frequently examines changes in cellular regulation, tissue maintenance and gene expression.
Short peptide bioregulators have been investigated in selected experimental models associated with these processes.
Relevant research topics include:
- Cellular ageing.
- Age-associated gene expression.
- Tissue-related molecular regulation.
- Experimental senescence models.
- Cellular stress responses.
- Protein-associated signalling.
- Molecular ageing research.
These investigations contribute to understanding age-associated cellular processes.
However, Cartalax has not been established as an anti-ageing treatment or a clinically effective method of preventing tissue degeneration.
7. Cartalax Compared With Other Peptide Bioregulators
Cartalax is sometimes discussed alongside other short synthetic peptides associated with experimental peptide-bioregulator research.
However, these compounds are not chemically or pharmacologically interchangeable.
Cartalax:
- Commonly identified as Ala–Glu–Asp (AED).
- A synthetic tripeptide.
- Associated with cartilage-related cellular research.
- Requires verification of the supplied molecular identity.
Pinealon:
- Commonly identified as Glu–Asp–Arg (EDR).
- A distinct synthetic tripeptide.
- Associated with experimental neuronal and cellular stress research.
- Has a different amino acid sequence.
Epitalon (Epithalon):
- Commonly identified as Ala–Glu–Asp–Gly (AEDG).
- A synthetic tetrapeptide.
- Associated with experimental cellular ageing and telomere biology research.
- Is not chemically equivalent to Cartalax.
Although these peptides are discussed within related research categories, findings involving one compound should not automatically be attributed to another.
8. Cartalax Analytical Characterisation and Quality Research
Cartalax is also relevant to analytical investigations involving synthetic peptide identity, structure and material quality.
Laboratories evaluating Cartalax may investigate:
- Confirmation of the Ala–Glu–Asp sequence.
- Amino acid composition.
- Molecular mass determination.
- Verification of terminal modifications.
- Chromatographic purity profiles.
- Related peptide impurities.
- Quantitative content determination.
- Stability and degradation characteristics.
- Batch-to-batch analytical consistency.
- Comparison with verified reference standards.
Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS) and other suitable methods.
A chromatographic purity result alone does not establish that a research preparation contains the expected AED sequence or declared quantitative content.
Analytical identity, purity and content are separate characteristics that should be evaluated using appropriate methods.
Cartalax 20mg Research Peptide Specifications
Peps Aussie lists Cartalax in a nominal 20mg size.
| Specification | Details |
|---|---|
| Product name | Cartalax |
| Listed size | 20mg |
| Peptide type | Synthetic tripeptide |
| Commonly reported sequence | Ala–Glu–Asp |
| One-letter sequence | AED |
| Amino acid length | 3 residues |
| Research classification | Experimental peptide bioregulator |
| Research category | Cartilage cell and tissue biology |
| Research areas | Chondrocyte models, gene expression, extracellular matrix and cellular regulation |
| Supplier | Peps Aussie Australia |
| Intended use | Laboratory research and analytical investigation only |
The scientific characteristics above describe Cartalax as discussed in published research. They do not independently verify the identity, composition, purity or content of the supplied material.
Exact molecular identity, amino acid sequence, stereochemistry, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.
Important: The commercial designation Cartalax does not independently establish that the supplied material has been analytically verified as Ala–Glu–Asp.
Cartalax Certificate of Analysis (COA) and Quality Documentation
Analytical verification is an important consideration when evaluating synthetic research peptides.
Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.
View Peps Aussie Certificates of Analysis
When evaluating Cartalax analytical documentation, researchers should consider:
- Peptide identity: Whether testing supports the declared Cartalax identity.
- Sequence verification: Whether the Ala–Glu–Asp sequence has been established.
- Molecular mass: Whether testing supports the expected molecular characteristics.
- Terminal modifications: Whether relevant terminal groups have been characterised.
- Purity assessment: Whether suitable methods were used to evaluate impurities.
- Content determination: Whether quantitative testing supports the declared 20mg quantity.
- Batch traceability: Whether the certificate corresponds to the supplied production lot.
- Testing methodology: Whether the analytical techniques are appropriate for the peptide.
- Additional testing: Whether relevant contamination or other quality assessments were performed.
High-performance liquid chromatography and mass spectrometry are commonly used in peptide characterisation.
However, a general purity result does not independently establish peptide identity, quantitative content or biological activity.
A certificate should be interpreted according to the tests actually performed.
The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.
Cartalax Storage and Laboratory Handling
Research peptides require appropriate handling to support sample integrity and experimental reproducibility.
Storage requirements for Cartalax depend on the molecular structure, formulation, packaging and validated manufacturer stability information.
Laboratories should consider:
- Appropriate storage temperature.
- Protection from light and moisture where necessary.
- Suitable laboratory containers.
- Compatibility with analytical solvents.
- Stability following sample preparation.
- Potential degradation during storage.
- Appropriate laboratory handling and disposal procedures.
No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.
Storage information from other peptide bioregulators should not automatically be applied to Cartalax.
All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.
Cartalax 20mg Australia – Product Availability and Shipping
Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.
Cartalax 20mg is the currently listed nominal product size.
Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.
For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.
Frequently Asked Questions About Cartalax
What is Cartalax?
Cartalax is a synthetic tripeptide commonly identified as Ala–Glu–Asp (AED) and associated with experimental peptide-bioregulator research.
What is Cartalax studied for?
Published cell-based investigations have considered cartilage-related cells, gene expression and broader tissue biology.
What is the amino acid sequence of Cartalax?
Cartalax is commonly described as Ala–Glu–Asp, abbreviated AED. The exact sequence of the supplied material should be confirmed through lot-specific documentation.
Is Cartalax a peptide bioregulator?
Cartalax is commonly discussed within experimental peptide-bioregulator research. However, that classification does not independently establish a therapeutic mechanism or clinical benefit.
Is Cartalax studied for cartilage?
Yes. Cartalax has been associated with published investigations involving cartilage-related cellular models and tissue biology.
Does Cartalax regenerate cartilage?
There is insufficient evidence to establish that Cartalax regenerates cartilage in humans. Laboratory observations should not be interpreted as proof of cartilage repair.
Is Cartalax studied for osteoarthritis?
Cartilage-related biological research may be relevant to understanding osteoarthritis-associated pathways, but this does not establish Cartalax as a treatment for osteoarthritis.
Does Cartalax improve joint health?
No established human clinical benefit has been demonstrated for the Peps Aussie research material. It is not supplied for joint health, pain relief or mobility improvement.
Is Cartalax the same as Epitalon?
No. Cartalax is commonly identified as the tripeptide AED, while Epitalon is commonly identified as the tetrapeptide AEDG.
Is Cartalax the same as Pinealon?
No. Cartalax and Pinealon have different amino acid sequences and research associations.
Is Cartalax approved for human use?
No medical approval or clinical suitability is claimed for the Peps Aussie Cartalax research product.
What size does Peps Aussie list?
Peps Aussie lists Cartalax in a 20mg nominal size. Researchers should verify the individual vial label and supporting analytical documentation.
Does Cartalax have a Certificate of Analysis?
Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.
How should Cartalax be stored?
Storage requirements depend on the formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.
Is Cartalax approved for veterinary use?
No veterinary approval or clinical suitability is claimed for the Peps Aussie research product.
It is not supplied for animal consumption, administration, diagnosis, prevention or treatment.
Cartalax Research Peptides at Peps Aussie Australia
Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, peptide chemistry and tissue-associated signalling.
Cartalax remains a subject of scientific interest because of its association with cartilage-related cellular models, gene expression and experimental peptide-bioregulator research.
Researchers evaluating Cartalax 20mg should prioritise accurate peptide identification, appropriate analytical documentation, batch traceability and validated laboratory procedures.
Explore the Peps Aussie research catalogue at pepsaussie.com.
Research Use Only Disclaimer
Cartalax 20mg is intended strictly for laboratory research and analytical purposes only.
This product is not intended for human or animal consumption, injection, administration, joint treatment, cartilage regeneration, therapeutic use or clinical treatment.
Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish cartilage repair, joint regeneration, osteoarthritis treatment, pain relief, clinical safety or therapeutic suitability for the material offered.
Findings involving related peptide bioregulators or experimental cellular models should not be assumed to apply to independently supplied Cartalax material without verified molecular identity and direct supporting evidence.
No dosing, self-administration or therapeutic guidance is provided.

Reviews
There are no reviews yet.